scholarly journals Pharmacokinetic Parameter Group Identifier

2020 ◽  
Author(s):  
Keyword(s):  
Pharmacokinetic Parameter ◽  
Parameter Group

scholarly journals ON TARGET SPACE DUALITY IN p-BRANES

1995 ◽  
Vol 10 (05) ◽  
pp. 441-450 ◽  
Author(s):  
R. PERCACCI ◽  
E. SEZGIN
Keyword(s):  
Dimensional Space ◽  
Target Space ◽  
Field Equations ◽  
Parameter Group ◽  
Duality Transformations ◽  
World Volume ◽  
The World ◽  
Dimensional Space Time ◽  
Background Fields ◽  
Two Parameter

We study the target space duality transformations in p-branes as transformations which mix the world volume field equations with Bianchi identities. We consider an (m+p+1)-dimensional space-time with p+1 dimensions compactified, and a particular form of the background fields. We find that while a GL (2) = SL (2) × R group is realized when m = 0, only a two-parameter group is realized when m > 0.

A spatially homogeneous gravitational field

1966 ◽  
Vol 62 (1) ◽  
pp. 87-89 ◽  
Author(s):  
V. Joseph
Keyword(s):  
Gravitational Field ◽  
Canonical Form ◽  
Riemann Tensor ◽  
Vacuum Field ◽  
Type I ◽  
Field Equations ◽  
Parameter Group ◽  
Spatially Homogeneous ◽  
Homogeneous Gravitational Field ◽  
Type V

AbstractA solution of Einstein's vacuum field equations, apparently new, is exhibited. The metric, which is homogeneous (that is, admits a three-parameter group of motions transitive on space-like hypersurfaces), belongs to Taub Type V. The canonical form of the Riemann tensor, which is of Petrov Type I, is determined.

Population Pharmacokinetics of Meropenem in Preterm Infants

2021 ◽  
Vol 76 (5) ◽  
pp. 497-505
Author(s):  
Irina B. Bondareva ◽  
Sergey K. Zyryanov ◽  
Aleksandra M. Kazanova
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Pharmacokinetic Parameter ◽  
Gestational Age ◽  
Drug Monitoring ◽  
Pharmacokinetic Parameters ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic ◽  
Pharmacokinetic Variability ◽  
Older Children ◽  
Term Neonates

Background. Meropenem, a broad spectrum carbapenem antibiotic, is often used for newborns despite of limited data available on neonatal pharmacokinetics. Due to pharmacokinetic and pharmacodynamic differences as well as to significant changes in the human body related to growth and maturation of organs and systems, direct scaling and dosing extrapolation from adults or older children with adjustment on patients weight can result in increased risk of toxicity or treatment failures. Aims to evaluate the pharmacokinetics of meropenem in premature neonates based on therapeutic drug monitoring data in real clinical settings. Materials. Of 53 pre-term neonates included in the pharmacokinetic/pharmacodynamic analysis, in 39 (73.6%) patients, gestational age ranged from 23 to 30 weeks. Population and individual pharmacokinetic parameter values were estimated by the NPAG program from the Pmetrics package based on peak-trough therapeutic drug monitoring. Samples were assayed by high-performance liquid chromatography. One-compartment pharmacokinetic model with zero-order input and first-order elimination was used to fit concentration data and to predict pharmacokinetic parameter (%T MIC of free drug) for virtual patients with simulated fast, moderate and slow meropenem elimination received different dosage by minimum inhibitory concentration (MIC) level. Univariate and multivariate regression analysis was used to evaluate the influence of patients covariates (gestational age, postnatal age, postconceptual age, body weight, creatinine clearance calculated by Schwartz formula, etc) on estimated meropenem pharmacokinetic parameters. Results. The identified population pharmacokinetic parameters of meropenem in pre-term newborns (elimination half-lives T1/2 = 1.93 0.341 h; clearance CL = 0.26 0.085 L/h/ kg; volume of distribution V = 0.71 0.22 L/h) were in good agreement with those published in the literature for adults, neonates and older children. Pharmacokinetic/pharmacodynamic modeling demonstrated that a meropenem dosage regimen of 90 mg/kg/day administered using prolonged 3-hour infusion every 8 hours should be considered as potentially effective therapy if nosocomial infections with resistant organisms (MIC 8 mg/L) are treated. Conclusions. Neonates and especially pre-term neonates have a great pharmacokinetic variability. Meropenem dosing in premature newborns derived from population pharmacokinetic/pharmacodynamic model can partly overcome the variability, but not all pharmacokinetic variability can be explained by covariates in a model. Further personalizing based on Bayesian forecasting approach and a patients therapeutic drug monitoring data can help to achieve desired pharmacodynamic target.

Derivations Tangential to Compact Group Actions: Spectral Conditions in the Weak Closure

1985 ◽  
Vol 37 (1) ◽  
pp. 160-192 ◽  
Author(s):  
Ola Bratteli ◽  
Frederick M. Goodman
Keyword(s):  
Finite Elements ◽  
Common Core ◽  
Dimensional Space ◽  
List Type ◽  
Finite Dimensional Space ◽  
Type Number ◽  
Compact Lie Group ◽  
Parameter Group ◽  
Finite Dimensional ◽  
Image Position

Let G be a compact Lie group and a an action of G on a C*-algebra as *-automorphisms. Let denote the set of G-finite elements for this action, i.e., the set of those such that the orbit {αg(x):g ∊ G} spans a finite dimensional space. is a common core for all the *-derivations generating one-parameter subgroups of the action α. Now let δ be a *-derivation with domain such that Let us pose the following two problems:Is δ closable, and is the closure of δ the generator of a strongly continuous one-parameter group of *-automorphisms?If is simple or prime, under what conditions does δ have a decompositionwhere is the generator of a one-parameter subgroup of α(G) and is a bounded, or approximately bounded derivation?

Sign in / Sign up

Export Citation Format

Share Document